SecBot SecBot
8-K ·Filed Apr 30, 2026

TELA

TELA Bio, Inc.
MIXED
Impact 6/10
Horizonweeks Processed6mo ago SEC0001104659-26-053102
8-K Item 2.02: Earnings release
Actionable Insight ◆ Mixed

The board overhaul introduces execution risk despite strong incoming director credentials. Watch for the Q1 2026 10-Q (due May 2026) for full financials and any strategic pivot under new leadership. The non-independent Chairman nomination is unusual and may raise governance concerns with institutional investors.

DirectionMixed
Confidencemedium
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$0.9890
T+0 close · Apr 30, 2026 · via day close
Latest settled
−32.24%
T+60 · $0.6701
Vs SPY
−35.31%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 1 $0.9890entry
  2. T+1 · 7mo ago +10.21%α +10.55% · $1.09
  3. T+5 · 6mo ago +11.22%α +8.88% · $1.10
  4. T+20 · 6mo ago −9.00%α −14.28% · $0.9000
  5. T+60 · 4mo ago −32.24%α −35.31% · $0.6701
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

TELA Bio reported preliminary Q1 2026 revenue of ~$19.0M, slightly above the $18.5M consensus, but the filing is dominated by a near-total board overhaul: Chairman Doug Evans and three other directors are resigning, replaced by four new directors including a non-independent Chairman nominee. The board refresh, while bringing experienced MedTech executives, introduces uncertainty about strategic direction and governance stability.

Key Financial Metrics

Revenue
$19.0M
est $18.5M · +2.7%

Key Facts

  • Preliminary Q1 2026 revenue of ~$19.0M, vs $18.5M consensus and prior Q1 guidance of ~$18.5M
  • Chairman Doug Evans and three other directors (Kurt Azarbarzin, Vince Burgess, Federica O'Brien) resigning effective after 2026 Annual Meeting
  • Joseph Capper (CEO of MiMedx) nominated as Class I director and proposed as Chairman, not expected to qualify as independent
  • Three new directors appointed: Guido Neels (EW Healthcare), Guy Nohra (Alta Partners), Paul Thomas (Prominex CEO), all deemed independent
  • Board refresh follows prior Q4 2025 earnings beat (EPS -$0.17 vs -$0.19 consensus) and 18% YoY revenue growth
  • Company guided 2026 revenue growth of at least 8% in March 2026 earnings call

Financial Impact

Preliminary Q1 2026 revenue ~$19.0M, ~2.7% above $18.5M consensus; no EPS or profitability data provided

revenue

Risk Factors

  • Board instability and governance concerns with non-independent Chairman
  • Preliminary revenue is unaudited and subject to revision
  • Company remains unprofitable with $38.8M net loss in FY2025 and $55.7M in long-term debt

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
82% bullish (11 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001104659-26-053102
Document: 0001104659-26-053102-index-headers.html0001104659-26-053102
Document: 0001104659-26-053102-index.html0001104659-26-053102
Document: 0001104659-26-053102.txt0001104659-26-053102
8-K Data (Synthetic)0001104659-26-053102

Track record

20 reports on TELA

Performance horizon

2 of 3 bullish or bearish reports moved the stock their way by T+5. Best: +18.61% at T+5 after the Aug 10, 2026 report. 4 of 5 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $0.7610 Now $0.7620 +0.13% settles Nov 23
  2. Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $0.8200 Now $0.7620 −7.07% settles Nov 23
  3. Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $0.8201 Now $0.7620 −7.08% settles Nov 23
  4. Nov 10, 20266d ago S-3 Bearish 5/10 Entry $0.9418 Now $0.7620 +19.09% settles Nov 18
  5. Nov 10, 20266d ago Press Release Bearish 5/10 Entry $0.9418 Now $0.7620 +19.09% settles Nov 18
  6. Oct 27, 202620d ago Press Release Neutral 2/10 Entry $0.9760 to $0.8378 Now $0.7620 −21.93% ▼ −14.16% −13.45% vs SPY
  7. Oct 6, 20265w ago 8-K Neutral 3/10 Entry $1.07 to $1.10 Now $0.7620 −28.79% ▲ +2.34% +3.32% vs SPY
  8. Oct 5, 20266w ago 8-K Bullish 5/10 Entry $1.14 to $1.08 Now $0.7620 −33.16% ▼ −5.26% −5.69% vs SPY
  9. Aug 31, 202611w ago 8-K Mixed 6/10 Entry $0.7380 to $0.8301 Now $0.7620 +3.25% ▲ +12.48% +12.62% vs SPY
  10. Aug 10, 202614w ago 8-K Bearish 7/10 Entry $0.7900 to $0.6430 Now $0.7620 +3.54% ▲ +18.61% +18.20% vs SPY
Showing 10 of 20

US Market Status

Market Closed · Opens in 6h 5m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 30, 2026